How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

344 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

the following sensitive cytochrome P450 (CYP) 3A4 substrate medications are excluded from the study unless they can be transferred to other medications prior to enrolling: alfentanil, aprepitant, budesonide, buspirone, conivaptan, darifenacin, darunavir, dronedarone, eletriptan, eplerenone, felodipine, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, quetiapine, saquinavir, sildenafil, simvastatin, tolvaptan, tipranavir, triazolam, ticagrelor, vardenafil

2014 Clinical Trials

142. Surveillance and Treatment of Prisoners With Hepatitis C

inhibitors: Tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), emtricitabine (FTC)Non-nucleoside reverse transcriptase inhibitors: Rilpivirine Protease inhibitors: Atazanavir, darunavir, lopinavir, ritonavir Integrase inhibitors: Dolutegravir, raltegravir, elvitegravir/cobicistat Contraindicated ARV include: Efavirenz (50% reduction in velpatasvir exposure) Didanosine Zidovudine Tipranavir Other ARV agents may be permissible at the time of study commencement pending further drug-drug

2014 Clinical Trials

143. Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers

: Completed First Posted : July 21, 2014 Last Update Posted : July 21, 2014 Sponsor: Boehringer Ingelheim Information provided by (Responsible Party): Boehringer Ingelheim Study Details Study Description Go to Brief Summary: Study to determine the effects of single-dose and steady-state TPV/RTV 500/200 mg on the steady-state pharmacokinetics of fluconazole Condition or disease Intervention/treatment Phase Healthy Drug: Tipranavir (TPV) Drug: Ritonavir (RTV) Drug: Fluconazole (FCZ) Phase 1 Study Design Go (...) Completion Date : July 2003 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: TPV + RTV + FCZ Drug: Tipranavir (TPV) 500 mg bid on days 7-14 Drug: Ritonavir (RTV) 200 mg bid on days 7-14 Drug: Fluconazole (FCZ) 200 mg loading dose on day 1, followed by 100 mg qd until day 13 Outcome Measures Go to Primary Outcome Measures : Area under plasma concentration time curve from 0-24 hours (AUC0-24h) for FCZ [ Time

2014 Clinical Trials

144. A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

regimen will switch to ABC/DTG/3TC FDC and be followed for an additional 24 weeks. Individuals initially randomly assigned to ABC/DTG/3TC FDC will continue on that treatment arm for an additional 24 weeks. A pharmacokinetic (PK) substudy will be conducted at a small number of sites (approximately 10) to evaluate predose DTG concentrations as well as residual drug concentrations of efavirenz (EFV), nevaripine (NVP), amprenavir (APV) and tipranavir (TPV) in a subgroup of subjects who switch from EFV (...) , NVP, fosamprenavir/ritonavir (FPV/r) or tipranavir/ritonavir (TPV/r). Condition or disease Intervention/treatment Phase Infection, Human Immunodeficiency Virus Drug: ABC/DTG/3TC FDC Drug: Ongoing cART regimen Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 555 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: 201147: a Phase

2014 Clinical Trials

145. Stribild - elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil

-associated mutation TDF tenofovir disoproxil fumarate (Viread ® ) TFV tenofovir TLOVR time to loss of virologic response TPV tipranavir TSH thyroid-stimulating hormone TVD emtricitabine/tenofovir disoproxil fumarate, coformulated (Truvada ® ) UGT uridine glucuronosyltransferase ULN upper limit of the normal range US/USA United States/United States of America VLDL very low-density lipoprotein WBC white blood cell ZDV zidovudine AUC area under the plasma concentration-time curve AUC 0-last area under

2013 European Medicines Agency - EPARs

146. Tybost - cobicistat

-tablet regimen TDF tenofovir disoproxil fumarate (Viread ? ) TFV tenofovir TLOVR time to loss of virologic response TPV tipranavir TVD emtricitabine/tenofovir disoproxil fumarate, coformulated (Truvada ? ) UGT uridine diphosphate glucuronosyltransferase ULN upper limit of the normal range ZDV zidovudine Assessment report Page 6/86 1. Background information on the procedure 1.1. Submission of the dossier The applicant Gilead Sciences International Ltd submitted on 26 April 2012 an application

2013 European Medicines Agency - EPARs

147. Vitekta - elvitegravir

EVG/r and tipranavir (TPV/r) GS-US-183-0123 multiple-dose DDI EVG/r and fosamprenavir (FPV)/r GS-US-183-0120 multiple-dose DDI EVG/r and darunavir (DRV)/r GS-US-183-0147 multiple-dose DDI EVG and ATV GS-US-183-0106 and -0108 effect of ATV/r on boosted EVG EVG and COBI GS-US-201-0104 evaluated the PK of EVG and COBI when co- administered with DRV GS-US-216-0116 EVG administered with 2 formulations of COBI GS-US-216-0123 evaluated unboosted ATV, rosuvastatin and dose-reduced rifabutin on EVG

2013 European Medicines Agency - EPARs

148. Teratology and Drug Use During Pregnancy (Treatment)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

149. Teratology and Drug Use During Pregnancy (Overview)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

150. HIV Nephropathy (Overview)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

152. Teratology and Drug Use During Pregnancy (Follow-up)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

154. HIV Nephropathy (Follow-up)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

155. Body Fluid Exposures (Follow-up)

agents are not recommended to be used for PEP because of their potential toxicity: Nevirapine Didanosine Nelfinavir Tipranavir High-risk exposures If the source is known to have HIV and is undergoing HIV treatment, an alternate regimen may be required because of the possibility of resistance; if possible, an HIV specialist should be consulted (see Consultations). Adherence Failure to complete courses of recommended regimens has been due to adverse effects, such as headache, diarrhea, or nausea

2014 eMedicine Emergency Medicine

156. Teratology and Drug Use During Pregnancy (Diagnosis)

damage (probably reversible) to immature nephrons. In addition, inner ear damage or hearing defects have been induced in utero in rats and guinea pigs exposed to streptomycin and/or kanamycin. Antiretrovirals (Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine, Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Atazanavir, Darunavir, Fosamprenavir, Indinavir, Lopinavir/ritonavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir, Raltegravir

2014 eMedicine.com

157. HIV Nephropathy (Diagnosis)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

158. Body Fluid Exposures (Treatment)

agents are not recommended to be used for PEP because of their potential toxicity: Nevirapine Didanosine Nelfinavir Tipranavir High-risk exposures If the source is known to have HIV and is undergoing HIV treatment, an alternate regimen may be required because of the possibility of resistance; if possible, an HIV specialist should be consulted (see Consultations). Adherence Failure to complete courses of recommended regimens has been due to adverse effects, such as headache, diarrhea, or nausea

2014 eMedicine Emergency Medicine

159. HIV Nephropathy (Treatment)

, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, lopinavir, atazanavir, tipranavir, darunavir) may precipitate nephrolithiasis. A classic form of this is crystalluria with the older agent indinavir, which occurs independently of renal function; however, the stones resolve after cessation of indinavir therapy. A study by Rockwood et al found that the rate of kidney stones was 7.3 per 1000 patient-years in patients receiving ritonavir-boosted atazanavir compared with 1.9 per 1000 patient years

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>